PT3324932T - Composições e métodos para formas de liófilos de nanopartículas - Google Patents

Composições e métodos para formas de liófilos de nanopartículas

Info

Publication number
PT3324932T
PT3324932T PT168286029T PT16828602T PT3324932T PT 3324932 T PT3324932 T PT 3324932T PT 168286029 T PT168286029 T PT 168286029T PT 16828602 T PT16828602 T PT 16828602T PT 3324932 T PT3324932 T PT 3324932T
Authority
PT
Portugal
Prior art keywords
nanoparticle
compositions
methods
lyophile forms
lyophile
Prior art date
Application number
PT168286029T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of PT3324932T publication Critical patent/PT3324932T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT168286029T 2015-07-22 2016-07-22 Composições e métodos para formas de liófilos de nanopartículas PT3324932T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562195356P 2015-07-22 2015-07-22

Publications (1)

Publication Number Publication Date
PT3324932T true PT3324932T (pt) 2021-04-06

Family

ID=57834582

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168286029T PT3324932T (pt) 2015-07-22 2016-07-22 Composições e métodos para formas de liófilos de nanopartículas

Country Status (23)

Country Link
US (3) US10300018B2 (cg-RX-API-DMAC7.html)
EP (1) EP3324932B1 (cg-RX-API-DMAC7.html)
JP (2) JP6875373B2 (cg-RX-API-DMAC7.html)
KR (1) KR102716928B1 (cg-RX-API-DMAC7.html)
CN (2) CN113679689B (cg-RX-API-DMAC7.html)
AU (1) AU2016297153B2 (cg-RX-API-DMAC7.html)
CA (1) CA2992849C (cg-RX-API-DMAC7.html)
CY (1) CY1123984T1 (cg-RX-API-DMAC7.html)
DK (1) DK3324932T3 (cg-RX-API-DMAC7.html)
EA (1) EA035761B1 (cg-RX-API-DMAC7.html)
ES (1) ES2862191T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210523T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053990T2 (cg-RX-API-DMAC7.html)
IL (2) IL288342B2 (cg-RX-API-DMAC7.html)
LT (1) LT3324932T (cg-RX-API-DMAC7.html)
MX (1) MX373982B (cg-RX-API-DMAC7.html)
PL (1) PL3324932T3 (cg-RX-API-DMAC7.html)
PT (1) PT3324932T (cg-RX-API-DMAC7.html)
RS (1) RS61607B1 (cg-RX-API-DMAC7.html)
SI (1) SI3324932T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100196T1 (cg-RX-API-DMAC7.html)
TW (1) TWI732773B (cg-RX-API-DMAC7.html)
WO (1) WO2017015552A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288342B2 (en) * 2015-07-22 2024-02-01 Nitto Denko Corp Compositions and methods for nanoparticle lyophile forms
CA3085694A1 (en) 2017-12-12 2019-06-20 Lead Biotherapeutics Ltd. Solid lipid nanoparticle for intracellular release of active substances and method for production the same
CN108813619A (zh) * 2018-07-19 2018-11-16 广州市汉廷食品有限公司 一种无公害食品添加剂及其制备工艺
AU2019347774A1 (en) 2018-09-28 2021-03-25 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
EP4365289A3 (en) * 2018-11-16 2024-07-10 Nitto Denko Corporation Rna interference delivery formulation and methods for malignant tumors
JP7597334B2 (ja) * 2019-09-26 2024-12-10 日油株式会社 脂質ナノ粒子の凍結乾燥組成物
AU2021228236A1 (en) * 2020-02-28 2022-10-06 Microcures, Inc. Fidgetin-like 2 as a target to enhance wound healing
WO2021216541A1 (en) * 2020-04-20 2021-10-28 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
IL300519A (en) * 2020-08-14 2023-04-01 Arcturus Therapeutics Inc Method for lyophilization of lipid nanoparticles
WO2022071582A1 (ja) 2020-10-02 2022-04-07 国立大学法人北海道大学 脂質ナノ粒子
EP4416287A1 (en) 2021-10-14 2024-08-21 Hemoshear Therapeutics, Inc. Compositions and methods of treating diseases associated with bile acid transporter
KR102712873B1 (ko) * 2021-12-20 2024-10-04 고려자연식품(주) 과일향기 포집을 위한 나노 지질 전달체 제조와 분말화 방법
CN116643056B (zh) * 2022-02-15 2025-02-18 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
US20240254485A1 (en) 2023-01-13 2024-08-01 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof
WO2025015189A1 (en) * 2023-07-13 2025-01-16 Comanche Biopharma Corp. Formulations of nucleic acid compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537683A (en) 1982-02-01 1985-08-27 Rohm And Haas Company Trihalomethane precursor removal using ion exchange emulsions
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
PT2277551E (pt) * 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
AU2004251680B2 (en) * 2003-06-04 2010-02-18 Georgetown University Method for improving stability and shelf-life of liposome complexes
US20060110441A1 (en) 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
JP2008520600A (ja) * 2004-11-19 2008-06-19 ノヴォソム アクチェンゲゼルシャフト 局所投与のための医薬組成物におけるまたはそれに関する改善
JP5334170B2 (ja) * 2007-02-09 2013-11-06 国立大学法人 奈良先端科学技術大学院大学 C70含有リポソームおよびその製造方法、並びにその利用
EP2509634B1 (en) * 2009-12-11 2019-03-06 Pfizer Inc Stable formulations for lyophilizing therapeutic particles
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN102018672B (zh) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 一种水溶性药物的脂质体冻干组合物及其制备方法
CA3198966A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Cleavable lipids
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
RU2648753C2 (ru) 2011-10-21 2018-03-28 Селатор Фармасьютикалз Инк. Лиофилизированные липосомы
US9579338B2 (en) * 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
EP3673898A1 (en) 2011-11-04 2020-07-01 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
KR102123129B1 (ko) 2012-03-28 2020-06-15 디스커버리 라보라토리스, 인크. 합성 리포솜 폐 계면활성제의 동결건조
HK1206644A1 (en) * 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
CA2876148C (en) 2012-06-08 2021-01-12 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
US20140271815A1 (en) 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
IL288342B2 (en) * 2015-07-22 2024-02-01 Nitto Denko Corp Compositions and methods for nanoparticle lyophile forms

Also Published As

Publication number Publication date
IL257029A (en) 2018-03-29
US20190231695A1 (en) 2019-08-01
AU2016297153A1 (en) 2018-03-01
CN108024957B (zh) 2021-08-24
US20170020819A1 (en) 2017-01-26
ES2862191T3 (es) 2021-10-07
KR102716928B1 (ko) 2024-10-11
US10300018B2 (en) 2019-05-28
EA201890367A1 (ru) 2018-06-29
EP3324932B1 (en) 2021-03-10
RS61607B1 (sr) 2021-04-29
JP6875373B2 (ja) 2021-05-26
IL257029B (en) 2021-12-01
MX2018000891A (es) 2018-06-11
JP2021119161A (ja) 2021-08-12
LT3324932T (lt) 2021-04-26
IL288342B2 (en) 2024-02-01
CY1123984T1 (el) 2022-05-27
SI3324932T1 (sl) 2021-07-30
MX373982B (es) 2020-07-15
TWI732773B (zh) 2021-07-11
JP2018521083A (ja) 2018-08-02
IL288342A (en) 2022-01-01
EP3324932A1 (en) 2018-05-30
SMT202100196T1 (it) 2021-05-07
WO2017015552A1 (en) 2017-01-26
EA035761B1 (ru) 2020-08-06
US12311055B2 (en) 2025-05-27
US11737982B2 (en) 2023-08-29
US20240000710A1 (en) 2024-01-04
PL3324932T3 (pl) 2021-07-05
IL288342B1 (en) 2023-10-01
CA2992849C (en) 2023-06-13
AU2016297153B2 (en) 2021-02-25
DK3324932T3 (da) 2021-04-06
EP3324932A4 (en) 2019-03-06
HUE053990T2 (hu) 2021-08-30
TW201717914A (zh) 2017-06-01
CN113679689B (zh) 2023-09-01
HRP20210523T1 (hr) 2021-05-14
KR20180030698A (ko) 2018-03-23
JP7268079B2 (ja) 2023-05-02
CN108024957A (zh) 2018-05-11
CA2992849A1 (en) 2017-01-26
BR112018001178A2 (pt) 2018-09-11
CN113679689A (zh) 2021-11-23

Similar Documents

Publication Publication Date Title
IL288342A (en) Formulations and methods for lyophilic nanoparticulate forms
IL286025A (en) Nanoparticle preparations and immunotherapy methods
IL259576A (en) Preparations and methods for immuno-oncology
GB2546350B (en) Compositions and methods
GB2535253B (en) Compositions and methods
GB201718801D0 (en) Compositions and methods for inhibiting factor D
GB201718876D0 (en) Antithrombin-heparin compositions and methods
IL258292A (en) Methods and compositions for reducing metastases
PT3200815T (pt) Métodos e composições para o tratamento de cancro
IL246879A0 (en) Preparations of Epilimod and methods of using them
ZA201605109B (en) Compositions and methods for treating neutropenia
IL258222A (en) Compositions and methods for inhibiting beta-lactamase
GB201715820D0 (en) Compositions and methods
GB201705626D0 (en) Compositions and methods
IL253174B (en) Nano-particles and methods for their preparation
GB201512996D0 (en) Compositions and methods
ZA201807665B (en) Methods and compositions
PT3160263T (pt) Composições para prevenção de infeções
GB201514413D0 (en) Compositions and methods
GB201520755D0 (en) Nanoparticle formulations and their uses
GB201402915D0 (en) Compositions and methods
ZA201807782B (en) Methods and compositions
IL256261B (en) Hide1 compositions and methods
GB201521306D0 (en) Compositions comprising nanoparticles and methods thereof
GB201521083D0 (en) Compositions for treatment and methods thereof